---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-258466"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2026-06-05T12:10:26+00:00"
generated_at: "2026-06-05T12:15:32.217716+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma annual meeting reelects Mack and Stelzer as Class III directors

## Summary
- David H. Mack, Ph.D. elected with 15,693,907 for, 6,248,461 withheld; Laurie Stelzer with 11,261,111 for, 10,681,257 withheld.
- Non-binding say-on-pay resolution approved: 15,015,578 for, 6,468,718 against, 458,072 abstain.
- Ernst & Young ratified as independent auditor for FY2026: 28,379,108 for, 536,302 against, 2,370 abstain.
- Broker non-votes on director election and say-on-pay totaled 6,975,412 shares.

## SEC filing metadata
- accession: 0001193125-26-258466
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2026-06-05T12:10:26+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000119312526258466/0001193125-26-258466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000119312526258466/d94814d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-258466
- JSON: https://secwatch.observer/filing/0001193125-26-258466.json
- Plain text: https://secwatch.observer/filing/0001193125-26-258466.txt

## Key facts
- Shareholder Votes
  PMV Pharmaceuticals, Inc. shareholders approved Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2026-06-04 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The Company’s stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers as described in the Company’s definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 22, 2026 (the “Proxy Statement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312526258466/0001193125-26-258466-index.htm
- Shareholder Votes
  PMV Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The Company’s stockholders elected the two persons listed below as Class III Directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective director’s death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312526258466/0001193125-26-258466-index.htm
- Shareholder Votes
  PMV Pharmaceuticals, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-04
  source text: The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000119312526258466/0001193125-26-258466-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.